Proxicromil
| Names | |
|---|---|
| Preferred IUPAC name
5-Hydroxy-4-oxo-10-propyl-6,7,8,9-tetrahydro-4H-naphtho[2,3-b]pyran-2-carboxylic acid | |
| Other names
Proxicromilum
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C17H18O5 | |
| Molar mass | 302.326 g·mol−1 |
| Melting point | 219 °C (426 °F; 492 K) |
| Hazards | |
| Occupational safety and health (OHS/OSH): | |
Main hazards
|
May cause cancer |
| GHS labelling: | |
| Danger | |
| H350 | |
| P301+P312+P330, P308+P313 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
| |
Proxicromil is a detergent-like, lipophilic oral medication developed in the late 1970s that was not admitted on the market because of its possible carcinogenic effects. It suppresses allergic reactions by binding to FcεRI receptor in mast cells, thereby inhibiting production of histamines. It is absorbed through the gastrointestinal tract, and has been proven hepatotoxic for dogs as a result of its accumulation in biliary canaliculi.